Mapping clinical CAR-T cells using scRNA-seq
The use of single cell RNA sequencing (scRNA-seq) in chimeric antigen receptor (CAR)-T cell clinical trial correlative studies has increased over the past 5 years, demonstrating its feasibility and impact on the field.
ScRNA-seq studies from hematological cancers show that exhaustion phenotypes are linked to poor CAR-T cell therapy responses, and that balancing T cell cytotoxicity and memory phenotypes may enhance efficacy.
As scRNA-seq data reliability improves, the field is poised to generate more impactful findings, including gene signatures that may facilitate screening and prediction of therapeutic response.
Early scRNA-seq studies for solid and brain tumors show the feasibility and promising findings from incorporating scRNA-seq into correlative studies.
As the number of data sets grows, synthesizing findings across studies is crucial for identifying consistent mediators of CAR-T cell therapy success.
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(25)00293-X
